摘要
Abstract
Objective To investigate the serum levels of IL-4,IL-17,IFN-γ and,TGF-β in of patients with chronic lymphocytic leukemia and the clinical significance.Methods 40 patients first diagnosed with chronic lymphocytic leukemia at our hospital from June,2014 to March,2016 were selected as an initial diagnosis group,30 patients with stable conditions after 3 months' treatment a treatment group,and 30 healthy examinees from the same period a control group.The serum levels of IL-4,IL-17,IFN-γ and,TGF-β of the three groups were detected by ELISA method.The differences of IL-4,IL-17,IFN-γ,TGF-β,IFN-γ/IL-4,and TGF-β/IL-17 were compared among the three groups.Results The serum levels of IL-4 and IL-17 and TGF-β/IL-17 were significantly higher [(18.46±4.66)pg/ml vs.(12.73±5.22)pg/ml,(268.98±63.69)pg/ml vs.(135.25±78.42)pg/ml and (18.25±8.64) vs.(10.88±6.18)] and the serum level of IFN-T and IFN-γ/IL-4 were significantly lower [(21.14±4.47) pg/ml vs.(32.58±4.54)pg/ml and (8.07±4.70) vs.(14.21±6.31)] in the initial diagnosis group than in the control group (P ＜ 0.05).The serum levels of IL-4 and IL-17 and TGF-β/IL-17 were significantly lower [(13.61±4.38)pg/ ml vs.(18.46±4.66)pg/ml,(184.55±67.27)pg/ml vs.(268.98463.69)pg/ml,and (14.43±6.52) vs.(18.25±8.64)] and the serum level of IFN-γ and IFN-γ/IL-4 were significantly higher [(24.27±4.18) pg/ml vs.(21.14±4.47) pg/ ml and (11.06±7.05) vs.(8.07±4.70)] in the treatment group than in the initial diagnosis group (P ＜ 0.05).In the initial diagnosis group,the TGF-β/IL-17 gradually increased with Binet stage [(12.52±6.42),(17.66±8.37),(21.30±10.74)] and the IFN-γ/IL-4 gradually decreased with Binet stage [(10.22±2.85),(9.09±3.05),(7.78±2.46)],showing obvious relevance (P ＜ 0.05).Conclusions IFN-γ/IL-4 and TGF-β/IL-17 can obviously indicating the conditions of patients with chronic lymphocytic leukemia and be used as important clinical indexes for the disease nrogression and nrognosis prediction in CLL patients.关键词
慢性淋巴细胞白血病/白介素-4/白介素-17/干扰素-γ/血清转化生长因子-β/预后评价Key words
Chronic lymphocytic leukemia/IL-4/IL-17/IFN-γ/TGF-β/Prognosis prediction
